...
kalv-img

Kalvista Pharmaceuticals Inc, Common Stock

KALV

NMQ

$8.69

-$0.05

(-0.57%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$449.21M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
407.56K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.91
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$8.48 L
$16.88 H
$8.69

About Kalvista Pharmaceuticals Inc, Common Stock

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameKALVSectorS&P500
1-Week Return-11.42%-2.27%-0.57%
1-Month Return-16.84%-3.96%1.21%
3-Month Return-21.99%-9.7%7.57%
6-Month Return-29.12%-3.37%11.45%
1-Year Return-12.22%3.71%28.48%
3-Year Return-36.62%3.8%29.52%
5-Year Return-48.67%39.78%90.66%
10-Year Return-88.84%106.91%203.75%

Financials

Apr '20Apr '21Apr '22Apr '23Apr '245YR TREND
Total Revenue12.69M12.69M---[{"date":"2020-04-30","value":100,"profit":true},{"date":"2021-04-30","value":100,"profit":true},{"date":"2022-04-30","value":"-","profit":true},{"date":"2023-04-30","value":"-","profit":true},{"date":"2024-04-30","value":"-","profit":true}]
Cost of Revenue40.19K651.00K743.00K802.00K86.17M[{"date":"2020-04-30","value":0.05,"profit":true},{"date":"2021-04-30","value":0.76,"profit":true},{"date":"2022-04-30","value":0.86,"profit":true},{"date":"2023-04-30","value":0.93,"profit":true},{"date":"2024-04-30","value":100,"profit":true}]
Gross Profit12.65M12.04M(743.00K)(802.00K)(86.17M)[{"date":"2020-04-30","value":100,"profit":true},{"date":"2021-04-30","value":95.17,"profit":true},{"date":"2022-04-30","value":-5.87,"profit":false},{"date":"2023-04-30","value":-6.34,"profit":false},{"date":"2024-04-30","value":-681.17,"profit":false}]
Gross Margin99.68%94.87%(Infinity%)(Infinity%)(Infinity%)[{"date":"2020-04-30","value":100,"profit":true},{"date":"2021-04-30","value":95.17,"profit":true},{"date":"2022-04-30","value":null,"profit":false},{"date":"2023-04-30","value":null,"profit":false},{"date":"2024-04-30","value":null,"profit":false}]
Operating Expenses53.22M57.92M96.61M110.87M54.28M[{"date":"2020-04-30","value":48,"profit":true},{"date":"2021-04-30","value":52.24,"profit":true},{"date":"2022-04-30","value":87.14,"profit":true},{"date":"2023-04-30","value":100,"profit":true},{"date":"2024-04-30","value":48.96,"profit":true}]
Operating Income(40.53M)(57.92M)(96.61M)(110.87M)(140.44M)[{"date":"2020-04-30","value":-4053300000,"profit":false},{"date":"2021-04-30","value":-5792300000,"profit":false},{"date":"2022-04-30","value":-9661300000,"profit":false},{"date":"2023-04-30","value":-11087100000,"profit":false},{"date":"2024-04-30","value":-14044500000,"profit":false}]
Total Non-Operating Income/Expense13.12M12.58M15.36M20.20M9.24M[{"date":"2020-04-30","value":64.98,"profit":true},{"date":"2021-04-30","value":62.3,"profit":true},{"date":"2022-04-30","value":76.07,"profit":true},{"date":"2023-04-30","value":100,"profit":true},{"date":"2024-04-30","value":45.78,"profit":true}]
Pre-Tax Income(29.24M)(46.24M)(82.34M)(92.91M)(135.10M)[{"date":"2020-04-30","value":-2924000000,"profit":false},{"date":"2021-04-30","value":-4624400000,"profit":false},{"date":"2022-04-30","value":-8233900000,"profit":false},{"date":"2023-04-30","value":-9290700000,"profit":false},{"date":"2024-04-30","value":-13509600000,"profit":false}]
Income Taxes(124.00K)(1.75M)(13.83M)(18.05M)(8.45M)[{"date":"2020-04-30","value":-12400000,"profit":false},{"date":"2021-04-30","value":-175000000,"profit":false},{"date":"2022-04-30","value":-1382700000,"profit":false},{"date":"2023-04-30","value":-1805400000,"profit":false},{"date":"2024-04-30","value":-845200000,"profit":false}]
Income After Taxes(29.12M)(44.49M)(68.51M)(74.85M)(126.64M)[{"date":"2020-04-30","value":-2911600000,"profit":false},{"date":"2021-04-30","value":-4449400000,"profit":false},{"date":"2022-04-30","value":-6851200000,"profit":false},{"date":"2023-04-30","value":-7485300000,"profit":false},{"date":"2024-04-30","value":-12664400000,"profit":false}]
Income From Continuous Operations(29.12M)(46.24M)(82.34M)(92.91M)(126.64M)[{"date":"2020-04-30","value":-2911600000,"profit":false},{"date":"2021-04-30","value":-4624400000,"profit":false},{"date":"2022-04-30","value":-8233900000,"profit":false},{"date":"2023-04-30","value":-9290700000,"profit":false},{"date":"2024-04-30","value":-12664400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-04-30","value":"-","profit":true},{"date":"2021-04-30","value":"-","profit":true},{"date":"2022-04-30","value":"-","profit":true},{"date":"2023-04-30","value":"-","profit":true},{"date":"2024-04-30","value":"-","profit":true}]
Net Income(29.12M)(44.49M)(68.51M)(74.85M)(126.64M)[{"date":"2020-04-30","value":-2911600000,"profit":false},{"date":"2021-04-30","value":-4449400000,"profit":false},{"date":"2022-04-30","value":-6851200000,"profit":false},{"date":"2023-04-30","value":-7485300000,"profit":false},{"date":"2024-04-30","value":-12664400000,"profit":false}]
EPS (Diluted)(1.64)(2.40)(3.36)(3.36)(3.40)[{"date":"2020-04-30","value":-164,"profit":false},{"date":"2021-04-30","value":-240,"profit":false},{"date":"2022-04-30","value":-336,"profit":false},{"date":"2023-04-30","value":-336,"profit":false},{"date":"2024-04-30","value":-340,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

KALV
Cash Ratio 6.13
Current Ratio 6.87

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

KALV
ROA (LTM) -53.94%
ROE (LTM) -90.84%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

KALV
Debt Ratio Lower is generally better. Negative is bad. 0.17
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.83

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

KALV
Trailing PE NM
Forward PE NM
P/S (TTM) 107.42
P/B 3.21
Price/FCF NM
EV/R 76.33
EV/Ebitda NM
PEG NM

FAQs

What is Kalvista Pharmaceuticals Inc share price today?

Kalvista Pharmaceuticals Inc (KALV) share price today is $8.69

Can Indians buy Kalvista Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Kalvista Pharmaceuticals Inc (KALV) on Vested. To buy Kalvista Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KALV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Kalvista Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Kalvista Pharmaceuticals Inc (KALV) via the Vested app. You can start investing in Kalvista Pharmaceuticals Inc (KALV) with a minimum investment of $1.

How to invest in Kalvista Pharmaceuticals Inc shares from India?

You can invest in shares of Kalvista Pharmaceuticals Inc (KALV) via Vested in three simple steps:

  • Click on Sign Up or Invest in KALV stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Kalvista Pharmaceuticals Inc shares
What is Kalvista Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Kalvista Pharmaceuticals Inc (KALV) is $16.88. The 52-week low price of Kalvista Pharmaceuticals Inc (KALV) is $8.48.

What is Kalvista Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Kalvista Pharmaceuticals Inc (KALV) is

What is Kalvista Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Kalvista Pharmaceuticals Inc (KALV) is 3.21

What is Kalvista Pharmaceuticals Inc dividend yield?

The dividend yield of Kalvista Pharmaceuticals Inc (KALV) is 0.00%

What is the Market Cap of Kalvista Pharmaceuticals Inc?

The market capitalization of Kalvista Pharmaceuticals Inc (KALV) is $449.21M

What is Kalvista Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Kalvista Pharmaceuticals Inc is KALV

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top